Virtual event on Monday, May 23rd at 11:00 AM ET
The webinar will provide a detailed discussion on the current landscape and unmet
needs within blood grouping and donor disease screening
JERSEY, Channel Islands, May 12, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it will host a key opinion leader (KOL) webinar on the current landscape and unmet needs within blood grouping and donor disease screening on Monday, May 23, 2022 at 11:00am ET.
The virtual webinar will feature a presentation with slides from KOL Christophe Martinaud, MD, PhD followed by comments from Manuel O. Méndez, Chief Executive Officer of Quotient on its MosaiQ solution, designed to provide multimodal, multiplexed testing on a fully automated platform, delivering clinical and economic value to customers while transforming patient care.
A live question and answer session will follow. To register for the event, please click here.
Christophe Martinaud, MD, PhD is a medical doctor, specialist in laboratory medicine and a scientist focused on hemorrhagic shock. He is currently the medical director and the head of the Department of Medical Laboratories in charge of quality control, blood donation screening and immuno-hematological analysis of a French Blood Bank, which is is also a training and research center embracing blood products and cell therapy.
Prof. Christophe Martinaud works on French Lyophilized plasma and was the first to report data about its use in clinical routine. He focused his research in this field on hemostatic properties, clinical trials in civilian and military settings and hemovigilance reporting. Prof. Christophe Martinaud is professor of transfusion medicine, Vice-President of the French Society of Blood Transfusion and member of several experts’ board at the French Regulation Agency.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that it believes reshape the way diagnostics are practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient’s operations are based in Switzerland, Scotland and the US.
Forward Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company’s MosaiQ technology to infectious disease diagnostics), current estimates of fourth quarter and full year fiscal 2022 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.
The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Investor Relations, [email protected]; +41 22 545 52 26